These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9031616)

  • 1. Behçet's disease in patients with chronic myelogenous leukemia: possible role of interferon-alpha treatment in the occurrence of Behçet's symptoms.
    Budak-Alpdoğan T; Demirçay Z; Alpdoğan O; Direskeneli H; Ergun T; Bayik M; Akoğlu T
    Ann Hematol; 1997 Jan; 74(1):45-8. PubMed ID: 9031616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behcet's disease in a patient with chronic myelogenous leukemia under hydroxyurea treatment: a case report and review of the literature.
    Vaiopoulos G; Terpos E; Viniou N; Nodaros K; Rombos J; Loukopoulos D
    Am J Hematol; 2001 Jan; 66(1):57-8. PubMed ID: 11426495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behçet's disease induced by interferon therapy for chronic myelogenous leukemia.
    Segawa F; Shimizu Y; Saito E; Kinoshita M
    J Rheumatol; 1995 Jun; 22(6):1183-4. PubMed ID: 7674251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin hyperreactivity of Behçet's patients (pathergy reaction) is also positive in interferon alpha-treated chronic myeloid leukaemia patients, indicating similarly altered neutrophil functions in both disorders.
    Budak-Alpdogan T; Demirçay ; Alpdogan O; Direskeneli H; Ergun T; Oztürk A; Günay A; Yavuz S; Uskent N; Akoğlu T
    Br J Rheumatol; 1998 Nov; 37(11):1148-51. PubMed ID: 9851260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of large genital ulcer due to hydroxyurea treatment in a patient with chronic myeloid leukemia and Behcet's disease.
    Karincaoglu Y; Kaya E; Esrefoglu M; Aydogdu I
    Leuk Lymphoma; 2003 Jun; 44(6):1063-5. PubMed ID: 12854911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of interferon-alpha(2a) on neutrophil adhesion and phagocytosis in chronic myeloid leukemia and Behçet's disease.
    Kartí SS; Ovalí E; Ratip S; Cetiner M; Direskeneli H; Bayik M; Akoğlu T
    Clin Rheumatol; 2002 Jun; 21(3):211-4. PubMed ID: 12111626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behçet's disease and comorbidity: internal case reports and literature review.
    Alekberova Z; Gorodetskiy V; Izmailova F; Radenska-Lopovok S; Talybova E; Evsikova M; Timoshin N; Nasonov E
    Rheumatol Int; 2015 Oct; 35(10):1743-7. PubMed ID: 25677835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of interferon-alpha in a case with Behçet's disease.
    Aoki T; Tanaka T; Akifuji Y; Ueki J; Nakamura I; Nemoto R; Ito K
    Intern Med; 2000 Aug; 39(8):667-9. PubMed ID: 10939544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behçet's disease associated with chronic myelogenous leukemia and chronic graft-vs-host disease.
    Cakmak SK; Gül U; Kiliç A; Gönül M; Soylu S; Demirel O
    Leuk Lymphoma; 2006 Dec; 47(12):2674-5. PubMed ID: 17169820
    [No Abstract]   [Full Text] [Related]  

  • 10. A novel case of renal pathergy reaction in a Behçet's disease patient complicated by IgA vasculitis.
    Higashihara T; Okada A; Kusano T; Ishigaki K; Shimizu A; Takano H
    BMC Nephrol; 2017 Jan; 18(1):40. PubMed ID: 28129738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.
    Park JY; Chung YR; Lee K; Song JH; Lee ES
    Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.
    Kötter I; Eckstein AK; Stübiger N; Zierhut M
    Br J Ophthalmol; 1998 May; 82(5):488-94. PubMed ID: 9713053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent epididymo-orchitis in patients with Behçet's disease.
    Kaklamani VG; Vaiopoulos G; Markomichelakis N; Kaklamanis P
    J Urol; 2000 Feb; 163(2):487-9. PubMed ID: 10647662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Behçet's disease with an onset prior to the appearance of chronic myeloid leukemia].
    Tassies D; Cervantes F; Feliu E; Cabal G; Martínez Orozco F; Rozman C
    Med Clin (Barc); 1992 Jun; 99(2):67-8. PubMed ID: 1630184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adamantiades-Behçet Disease at the Beginning of the Silk Route: North-East Italian Experience.
    Bergamo S; di Meo N; Stinco G; Bonin S; Trevisini S; Trevisan G
    Acta Dermatovenerol Croat; 2017 Dec; 25(4):295-297. PubMed ID: 30064603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheumatic diseases and chronic myelogenous leukemia, presentation of four cases and review of the literature.
    Senel S; Kaya E; Aydogdu I; Erkurt MA; Kuku I
    Rheumatol Int; 2006 Jul; 26(9):857-61. PubMed ID: 16404564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behçet's disease and Chiari's network.
    Alonso G; Santos E; Fuertes A; Jiménez A; Gutiérrez JA
    Clin Rheumatol; 2007 Dec; 26(12):2189-2190. PubMed ID: 17632744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synovial lymphoid neogenetic factors in Behçet's synovitis: do they play a role in self-limiting and subacute course of arthritis?
    Pay S; Musabak U; Simsek I; Erdem H; Pekel A; Sengul A; Dinc A
    Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S21-6. PubMed ID: 17949547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features of patients with Behçet's disease and epididymitis.
    Cho YH; Jung J; Lee KH; Bang D; Lee ES; Lee S
    J Urol; 2003 Oct; 170(4 Pt 1):1231-3. PubMed ID: 14501731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of transmembrane and soluble CXCL16 and the relation with interferon-alpha secretion in patients with Behçet's disease.
    Yilmaz S; Cinar M; Pekel A; Simsek I; Musabak U; Erdem H; Pay S
    Clin Exp Rheumatol; 2013; 31(3 Suppl 77):84-7. PubMed ID: 24064021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.